Drug Delivery Using Nanoparticles for Cancer Stem-Like Cell Targeting

Area of Science:

• Oncology
• Nanomedicine
• Cancer Biology

Background:

• Cancer stem-like cells (CSCs) explain tumor heterogeneity, progression, and therapeutic resistance.
• CSCs are crucial drivers of tumor growth and are key targets for novel cancer therapies.
• Targeting CSCs is essential for overcoming treatment resistance and preventing cancer recurrence.

Purpose of the Study:

• To review the current understanding of cancer stem cell research.
• To summarize state-of-the-art nanomedicine approaches for targeting CSCs.
• To discuss emerging epigenetic drug strategies for CSC elimination and reprogramming inhibition.

Main Methods:

• Review of existing literature on cancer stem cells and nanomedicine.
• Analysis of nanoparticle-based therapeutic strategies targeting CSC markers and pathways.
• Exploration of epigenetic drug applications in CSC eradication.

Main Results:

• Nanoparticles effectively inhibit various CSCs by targeting key markers (e.g., aldehyde dehydrogenases, CD44, CD90, CD133).
• Nanomedicine targets critical CSC signaling pathways like Notch, Hedgehog, and TGF-β.
• Epigenetic drugs offer a promising strategy to eliminate CSCs and prevent cancer cell reprogramming.

Conclusions:

• Nanomedicine presents effective strategies for targeting cancer stem cells.
• Epigenetic therapies are emerging as a vital approach to eliminate CSCs and overcome therapeutic resistance.
• Combined nanomedicine and epigenetic approaches hold significant potential for future cancer treatment.